TeleTech Holdings Inc. (NASDAQ:TTEC) shares moved down -2.60% in last trading session and ended the day at $25.14. TTEC Gross Margin is 28.10% and its has a return on assets of 7.70%. TeleTech Holdings Inc. (NASDAQ:TTEC) quarterly performance is -13.07%.
SunTrust cut shares of TeleTech Holdings, Inc. (NASDAQ:TTEC) from a buy rating to a neutral rating in a research report released on Tuesday, The Fly reports.
Symantec Corporation (NASDAQ:SYMC) shares moved down -1.94% in last trading session and ended the day at $20.25. SYMC Gross Margin is 82.40% and its has a return on assets of 5.20%. Symantec Corporation (NASDAQ:SYMC) quarterly performance is -1.10%.
Symantec Corporation (NASDAQ:SYMC) and The Carlyle Group (NASDAQ: CG) announced that they expect to close Carlyle’s acquisition of Veritas on January 29, 2016, subject to the satisfaction of customary closing conditions. The closing was previously expected to take place on January 1, 2016.
Gilead Sciences Inc. (NASDAQ:GILD) ended the last trading day at $92.54. Company weekly volatility is calculated as 3.54% and price to cash ratio as 8.49. Gilead Sciences Inc. (NASDAQ:GILD) showed a weekly performance of -7.74%.
On 5 January, Gilead Sciences Inc. (NASDAQ:GILD) announced that two Phase 3 clinical trials (Studies 108 and 110) evaluating investigational use of once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV) infection met their primary objectives.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) shares moved down -4.40% in last trading session and ended the day at $8.70. VNDA Gross Margin is 80.70% and its has a return on assets of 21.50%. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) quarterly performance is -13.86%.
On 11 January, Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) announced preliminary unaudited financial results for the fourth quarter and full year 2015 and its financial guidance for 2016. Vanda expects to report fourth quarter 2015 total net product sales from HETLIOZ® and Fanapt® of approximately $31.8 million.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) caters to the Healthcare space. Its weekly performance is -29.19%. On the last day of trading company shares ended up at $2.11. Ocera Therapeutics, Inc. (NASDAQ:OCRX) distance from 50-day simple moving average (SMA50) is 4.37%.
On 8 January, Ocera Therapeutics, Inc. (NASDAQ:OCRX) announced further details from its Phase 1 study of oral formulations of OCR-002, ornithine phenylacetate, in healthy subjects. The Company plans to conduct additional Phase 1 testing after further formulation optimization
Leave a Reply